Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-201 Acetate Injection in Healthy Volunteers and Ulcerative Colitis Patients
NCT06681389Phase 1Terminated
- Sponsor
- Nanotechnology and Integrated Bioengineering Centre
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing NP-201 Acetate Injection with Placebo (2 arms). Primary endpoints: Adverse Events at Day 12, Changes in baseline Laboratory values at Day 12 and 11 more. Started Nov 2024; status: terminated.
02
Drugs
NP-201
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06681389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681389.